{
    "nctId": "NCT05716516",
    "briefTitle": "STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)",
    "officialTitle": "Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Clinical Benefit Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal women with ER+ breast cancer.\n* Metastatic or locoregional recurrence not amenable to treatment with curative\n* intent.\n* Received \u22651 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting\n\nExclusion Criteria:\n\n* During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions:\n\n  * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion.\n  * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.\n* Any investigational cancer therapy in the last 3 weeks.\n* Known CNS disease, unless clinically stable for \u2265 3 months.\n* History of any of the following:\n\n  * Deep venous thrombosis.\n  * Pulmonary embolism.\n  * Stroke.\n  * Acute myocardial infarction.\n  * Congestive heart failure.\n  * Previous malignancy not treated with curative intent, or with an estimated recurrence risk \u226530%.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}